What’s New in “Hydroxychloroquine Retinopathy”
Article Sidebar
Published:
Feb 1, 2018
Keywords:
Hydroxychloroquine retinopathy bull’s eye maculopathy retinal diagnostics
Main Article Content
Abstract
Hydroxychloroquine has been widely used for treatment of autoimmune diseases for a long time due to its safety and having fewer side effects than any other immunosuppressive agents; but it can cause retinal toxicity that is irreversible and can progress even after drug cessation. Physicians should be concerned and perform proper eye screening tests to prevent loss of vision; and to avoid unnecessary drug cessation.
Article Details
How to Cite
Kurathong, S. (2018). What’s New in “Hydroxychloroquine Retinopathy”. Vajira Medical Journal : Journal of Urban Medicine, 62(1), 53–62. Retrieved from https://he02.tci-thaijo.org/index.php/VMED/article/view/196072
Section
Review Articles
References
1. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine - a reappraisal. Ophthalmology. 2003;110: 1321-6.
2. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775-84.
3. Kunavisarut P, Chavengsaksongkram P, Rothova A, Pathanapitoo K. Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing. Indian J Ophthalmol. 2016; 64(10):710-4.
4. Suansilpong A, Uaratanawong S. Accuracy of Amsler grid in screening for chloroquine retinopathy. J Med Assoc Thai. 2010;93: 462-6.
5. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, et al. Ocular toxicity of chloroquine among Thai patients. Int J Dermatol. 1999;38: 934-7.
6. Chiowchanwisawakit P, Nilganuwong S, Srinonpraser tV, Boonpraser tR, Chandranipapongse W, Chatsiricharoenkul S, et al. Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. Int J Rheum Dis. 2013;16: 47-55.
7. Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai. 2007;90: 52-8.
8. Srikua U, Aui-Aree N. Timing of chloroquine and hydroxychloroquine screening. Thai J Ophthalmol. 2008;22: 61-8.
9. Thongsin S. Chloroquine maculopathy in Chiang Rai Regional Hospital. Lampang Med J. 2010;31: 98-103.
10. Samsen P, Ruangvoravate N, Chiemchaisri Y, Parivisutti L. Chloroquine keratopathy. Thai J Ophthalmol. 1995;9: 167-73.
11. Tangtavorn N, Yospaiboon Y, Ratanapakorn T, Sinawat S, Sanguansak T, Bhoomibunchoo C, et al. Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologic patients. Clin Ophthalmol. 2016;10: 2179-85.
12. Dayhaw-Barker P. Retinal pigment epithelium melanin and ocular toxicity. Int J Toxicol. 2002;21(6): 451-4.
13. Marmor MF, Kellner U,Lai TY, Lyon JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118: 415-22.
14. Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci. 2015;56: 3415-26.
15. Marmor MF, Kellner U, Lai TY,Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-94.
16. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132: 1453-60.
17. Melles RB, Marmor MF. Pericentral Retinopathy and Racial Differences in Hydroxychloroquine Toxicity. Ophthalmology. 2015;122(1):110-6.
18. Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral Hydroxychloroquine Retinopathy in Korean Patient. Ophthalmology. 2015;122: 1252-6.
19. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132: 1105-12.
20. Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 2014;98(2): 200-6.
21. Marmor MF, Chien FY, Johnson MW. Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2013;131(4): 476-80.
22. Ahn SJ, Ryu SJ, Joung J, Lee BR. Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. Am J Ophthalmol. 2017;183: 56-64.
23. Ahn SJ, Joung J, Lim HW, Lee BR. Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients. Am J Ophthalmol. 2017;184: 11-18.
24. Marmor MF, Melles RB. Disparity between Visual Fields and Optical Coherence Tomography in Hydroxychloroquine Retinopathy. Ophthalmology. 2014 ;121(6): 1257-62.
25. Pandya HK, Robinson M, Mandal N, Shah VA. Hydroxychloroquine retinopathy: A review of imaging. Indian J Ophthalmol. 2015;63:570-4.
26. Jivrajka RV, Genead MA, McAnany JJ, Chow CC, Mieler WF. Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy. Eye. 2013;27(9): 1044-52.
27. Molina MA, Piñero DP, Pérez-Cambrodí RJ. Decreased perifoveal sensitivity detected by microperimetry in patients using hydroxychloroquine and without visual field and fundoscopic anomalies. J Ophthalmol. 2015;2015:437271.
28. Murray JJ, Lee MS. Re: Marmor et al.: American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2017;124(3): e28-9.
2. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775-84.
3. Kunavisarut P, Chavengsaksongkram P, Rothova A, Pathanapitoo K. Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing. Indian J Ophthalmol. 2016; 64(10):710-4.
4. Suansilpong A, Uaratanawong S. Accuracy of Amsler grid in screening for chloroquine retinopathy. J Med Assoc Thai. 2010;93: 462-6.
5. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, et al. Ocular toxicity of chloroquine among Thai patients. Int J Dermatol. 1999;38: 934-7.
6. Chiowchanwisawakit P, Nilganuwong S, Srinonpraser tV, Boonpraser tR, Chandranipapongse W, Chatsiricharoenkul S, et al. Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. Int J Rheum Dis. 2013;16: 47-55.
7. Leecharoen S, Wangkaew S, Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J Med Assoc Thai. 2007;90: 52-8.
8. Srikua U, Aui-Aree N. Timing of chloroquine and hydroxychloroquine screening. Thai J Ophthalmol. 2008;22: 61-8.
9. Thongsin S. Chloroquine maculopathy in Chiang Rai Regional Hospital. Lampang Med J. 2010;31: 98-103.
10. Samsen P, Ruangvoravate N, Chiemchaisri Y, Parivisutti L. Chloroquine keratopathy. Thai J Ophthalmol. 1995;9: 167-73.
11. Tangtavorn N, Yospaiboon Y, Ratanapakorn T, Sinawat S, Sanguansak T, Bhoomibunchoo C, et al. Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologic patients. Clin Ophthalmol. 2016;10: 2179-85.
12. Dayhaw-Barker P. Retinal pigment epithelium melanin and ocular toxicity. Int J Toxicol. 2002;21(6): 451-4.
13. Marmor MF, Kellner U,Lai TY, Lyon JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118: 415-22.
14. Sisternes L, Hu J, Rubin DL, Marmor MF. Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea. Invest Ophthalmol Vis Sci. 2015;56: 3415-26.
15. Marmor MF, Kellner U, Lai TY,Melles RB, Mieler WF. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-94.
16. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132: 1453-60.
17. Melles RB, Marmor MF. Pericentral Retinopathy and Racial Differences in Hydroxychloroquine Toxicity. Ophthalmology. 2015;122(1):110-6.
18. Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK, et al. Pericentral Hydroxychloroquine Retinopathy in Korean Patient. Ophthalmology. 2015;122: 1252-6.
19. Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132: 1105-12.
20. Kellner S, Weinitz S, Farmand G, Kellner U. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol. 2014;98(2): 200-6.
21. Marmor MF, Chien FY, Johnson MW. Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2013;131(4): 476-80.
22. Ahn SJ, Ryu SJ, Joung J, Lee BR. Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. Am J Ophthalmol. 2017;183: 56-64.
23. Ahn SJ, Joung J, Lim HW, Lee BR. Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients. Am J Ophthalmol. 2017;184: 11-18.
24. Marmor MF, Melles RB. Disparity between Visual Fields and Optical Coherence Tomography in Hydroxychloroquine Retinopathy. Ophthalmology. 2014 ;121(6): 1257-62.
25. Pandya HK, Robinson M, Mandal N, Shah VA. Hydroxychloroquine retinopathy: A review of imaging. Indian J Ophthalmol. 2015;63:570-4.
26. Jivrajka RV, Genead MA, McAnany JJ, Chow CC, Mieler WF. Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy. Eye. 2013;27(9): 1044-52.
27. Molina MA, Piñero DP, Pérez-Cambrodí RJ. Decreased perifoveal sensitivity detected by microperimetry in patients using hydroxychloroquine and without visual field and fundoscopic anomalies. J Ophthalmol. 2015;2015:437271.
28. Murray JJ, Lee MS. Re: Marmor et al.: American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2017;124(3): e28-9.